{
  "drug_name": "Fosfomycin po",
  "tradename": "Monurol",
  "usage_and_dosing": {
    "description": [
      "Fosfomycin is a low molecular weight (138) phosphonic acid derivative, available for over 20 years.",
      "Oral preparation is a tromethamine prodrug. The IV preparation is Fosfomycin disodium, see Fosfomycin IV.",
      "Unique mechanism of action: Inhibition of the synthesis of cell wall peptidoglycan, a key constituent of both gram-positive and gram-negative bacteria. Considered bactericidal with time-dependent killing.",
      "In vitro activity:",
      "In vitro activity includes ESBL-producing and carbapenem-resistant Enterobacteriaceae: Int J Antimicrob Ag 37:415, 2011. Some clinical success for UTIs reported: Antimicrob Agts Chemother 56:5744, 2012.",
      "Activity often enhanced when tested in combination: e.g., carbapenems increased Fosfomycin activity vs Ps. aeruginosa in a hollow-fiber infection model (Antimicrob Agents Chemother 2018; 62:e01682-18).",
      "Acinetobacter sp. and Bacteroides sp. are resistant.",
      "Gram-positive bacteria: Staph. aureus (including MRSA), Staph. epidermidis, Strep. pneumoniae, E. faecalis and VRE.",
      "Gram-negative bacteria: E. coli, Proteus species, Klebsiella/Enterobacter sp., Serratia sp., Salmonella sp., Citrobacter sp., Providencia sp.",
      "Resistance primarily chromosomal; rare plasmid-mediated resistance.",
      "Mechanisms: decrease in drug transport across the cell wall or enzymatic alteration of the drug (e.g., adding a glutathione).",
      "Cross resistance to other classes of antibiotics is rare.",
      "Clinical use:",
      "Most common: oral therapy for urinary tract infections (UTI).",
      "Availability:",
      "Oral formulation is widely available in Europe, U.S., Canada, South America, Japan and Australia."
    ],
    "adult_dose": {
      "uncomplicated_uti": "Fosfomycin tromethamine 3 gm po x1 dose",
      "complicated_uti": "Fosfomycin tromethamine 3 gm po q2-3 days x3 doses",
      "prostatitis": "Fosfomycin tromethamine 3 gm po q3 days x7 doses"
    },
    "pediatric_dose": {
      "dose_age_gt_28_days": "2 gm once",
      "max_day": "-"
    }
  },
  "renal_adjustment": {
    "guidance": [
        "Body weight and Creatinine Clearance calculations",
        "CrCl = Creatinine clearance (mL/min)",
        "CAPD = Continuous Ambulatory Peritoneal Dialysis",
        "CRRT = Continuous Renal Replacement Therapy",
        "AD = after hemodialysis",
        "SLED = sustained low efficiency dialysis"
    ],
    "half_life_hrs_renal_function_normal": "5.7",
    "half_life_hrs_esrd": "50",
    "dose_renal_function_normal": "3 gm po x1",
    "crcl_or_egfr": "CrCl 
10: no dosage adjustment
CrCl <10: Avoid use (poor urinary excretion)",
    "hemodialysis": "No data",
    "capd": "No data",
    "crrt": "No data",
    "sled": "No data"
  },
  "hepatic_adjustment": {
    "mild_impairment_child_pugh_class_a": "No data",
    "moderate_impairment_child_pugh_class_b": "No data",
    "severe_impairment_child_pugh_class_c": "No data"
  },
  "adverse_effects": [
    "Diarrhea in 9% compared to 6% of patients given nitrofurantoin and 2.3% given TMP-SMX.",
    "Headache reported in 4-10% of patients."
  ],
  "pregnancy_risk": {
    "fda_risk_category": "B",
    "use_during_lactation": "Probably safe with monitoring, but data limited"
  },
  "antimicrobial_spectrum": {
    "preferred": ["None"],
    "alternative": []
  },
  "pharmacology": {
    "pk_pd_index": "T>MIC",
    "pharmaceutical_preparations": "3 gm sachet",
    "food_rec_po_drugs": "Sachet + food",
    "oral_absorption_percent": "trometh 40",
    "tmax_hr": "2",
    "peak_serum_conc_ug_ml": "26.1 (3 gm po, SD)",
    "peak_urine_conc_ug_ml": "1053-4415 (4 hr after 3 gm)",
    "protein_binding_percent": "Negligible",
    "volume_of_distribution_vd": "136.1 L (Vss/F)",
    "avg_serum_t1_2_hr": "5.7",
    "elimination": "Renal",
    "bile_penetration_percent": "No data",
    "csf_blood_percent": "20-50",
    "therapeutic_levels_in_csf": "No",
    "auc_ug_hr_ml": "145-193 (3 gm po, 0-inf)"
  },
  "major_drug_interactions": [
    {
      "drug": "Metoclopramide",
      "effect_on_concentration": "
 fosfomycin (serum conc)",
      "suggested_management": "Avoid co-administra"
    },
    {
      "drug": "Probenecid",
      "effect_on_concentration": "
 fosfomycin urinary excretion",
      "suggested_management": "Avoid co-administra"
    }
  ],
  "comments": [
    "Homologues of the fosA resistance gene have been found in chromosomes of a large proportion of isolates from various gram-negative species (mBio 8: e00749-17, 2017).",
    "For in vitro activity (vs US bacterial isolates), see Diagn Microbiol Infect Dis 2019;93:143. Note low level of activity and/or variable activity vs:",
    "Acinetobacter baumannii",
    "Morganella species",
    "Pseudomonas aeruginosa",
    "Stenotrophomonas maltophilia",
    "Bacteroides fragilis",
    "Fusobacterium species"
  ]
}